Drug Review

Ivabradine – the first selective sinus node If channel inhibitor in the treatment of chronic stable angina with normal sinus rhythm.

Ivabradine is currently the only agent shown to clinically lower heart rate with no negative inotropism or effects on conduction and contractility. Lowering heart rate is therefore one of the most important therapeutic approaches in the treatment of stable angina pectoris, which reduces myocardial oxygen demand, simultaneously improving oxygen supply. Mechanism of action: Ivabradine acts on the If  ion current, which is highly expressed in the SA

Read more